NYSE:GKOS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. More Details


Snowflake Analysis

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has Glaukos's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GKOS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.5%

GKOS

0.4%

US Medical Equipment

-1.1%

US Market


1 Year Return

-12.5%

GKOS

20.9%

US Medical Equipment

15.0%

US Market

Return vs Industry: GKOS underperformed the US Medical Equipment industry which returned 22.2% over the past year.

Return vs Market: GKOS underperformed the US Market which returned 15.6% over the past year.


Shareholder returns

GKOSIndustryMarket
7 Day-3.5%0.4%-1.1%
30 Day9.6%5.6%2.9%
90 Day27.8%4.7%5.7%
1 Year-12.5%-12.5%22.0%20.9%17.6%15.0%
3 Year58.3%58.3%75.4%70.8%38.9%29.7%
5 Year187.0%187.0%137.2%118.8%78.4%58.4%

Price Volatility Vs. Market

How volatile is Glaukos's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Glaukos undervalued compared to its fair value and its price relative to the market?

3.76x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: GKOS ($59.57) is trading above our estimate of fair value ($25.8)

Significantly Below Fair Value: GKOS is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: GKOS is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: GKOS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GKOS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GKOS's PB Ratio (4x) is in line with the US Medical Equipment industry average.


Next Steps

Future Growth

How is Glaukos forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

61.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GKOS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GKOS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GKOS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GKOS's revenue (23.7% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: GKOS's revenue (23.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GKOS is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Glaukos performed over the past 5 years?

-1.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GKOS is currently unprofitable.

Growing Profit Margin: GKOS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GKOS is unprofitable, and losses have increased over the past 5 years at a rate of 1.1% per year.

Accelerating Growth: Unable to compare GKOS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GKOS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.9%).


Return on Equity

High ROE: GKOS has a negative Return on Equity (-10.7%), as it is currently unprofitable.


Next Steps

Financial Health

How is Glaukos's financial position?


Financial Position Analysis

Short Term Liabilities: GKOS's short term assets ($453.2M) exceed its short term liabilities ($54.8M).

Long Term Liabilities: GKOS's short term assets ($453.2M) exceed its long term liabilities ($278.5M).


Debt to Equity History and Analysis

Debt Level: GKOS's debt to equity ratio (27.8%) is considered satisfactory.

Reducing Debt: GKOS's debt to equity ratio has increased from 21.8% to 27.8% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GKOS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if GKOS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Glaukos's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GKOS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GKOS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GKOS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GKOS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GKOS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Thomas Burns (59 yo)

18.58yrs

Tenure

US$5,716,560

Compensation

Mr. Thomas William Burns has been the Chief Executive Officer and President at Glaukos Corporation since March 2002. He serves as Director of Avedro, Inc. since November 21, 2019. He serves as Independent ...


CEO Compensation Analysis

Compensation vs Market: Thomas's total compensation ($USD5.72M) is about average for companies of similar size in the US market ($USD5.63M).

Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Thomas Burns
CEO, President & Director18.58yrsUS$5.72m2.46%
$ 61.3m
Joseph Gilliam
CFO & Senior VP of Corporate Development3.42yrsUS$2.01m0.045%
$ 1.1m
Chris Calcaterra
Chief Operating Officer3.58yrsUS$2.05m0.34%
$ 8.6m
Mory Gharib
Co-Founderno datano datano data
Christopher Lewis
Director of Investor Relationsno datano datano data
Diane Biagianti
Senior VP & General Counsel0.25yrno datano data
Michele Allegretto
Senior Vice President of Human Resources5.42yrsno datano data
David Haffner
Senior Vice President of New Technologies3.58yrsno datano data
L. Katz
Chief Medical Officer3.58yrsno datano data
Jane Rady
Senior Vice President of Corporate Strategy & Business Development2.5yrsno datano data
Richard Harrison
3.42yrsUS$465.62kno data

3.6yrs

Average Tenure

60yo

Average Age

Experienced Management: GKOS's management team is considered experienced (3.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Thomas Burns
CEO, President & Director18.58yrsUS$5.72m2.46%
$ 61.3m
William Link
Independent Chairman of the Board19.33yrsUS$290.02k0.11%
$ 2.8m
Gilbert Kliman
Independent Director0.58yrUS$238.26k0.0019%
$ 46.6k
Richard Lindstrom
Member of Scientific Advisory Boardno datano datano data
Aimee Weisner
Independent Director6.25yrsUS$238.26k0.030%
$ 751.8k
Mark Foley
Independent Director6.25yrsUS$239.99k0.016%
$ 406.9k
David Hoffmeister
Independent Director6.25yrsUS$238.26k0.024%
$ 591.2k
Ike Ahmed
Member of Scientific Advisory Boardno datano datano data
Thomas Samuelson
Member of Scientific Advisory Boardno datano datano data
Marc Stapley
Independent Director6.25yrsUS$249.76k0.025%
$ 626.9k
Kuldev Singh
Member of Scientific Advisory Boardno datano datano data
Richard Lewis
Member of Scientific Advisory Boardno datano datano data

6.3yrs

Average Tenure

60yo

Average Age

Experienced Board: GKOS's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.3%.


Top Shareholders

Company Information

Glaukos Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Glaukos Corporation
  • Ticker: GKOS
  • Exchange: NYSE
  • Founded: 1998
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$2.494b
  • Shares outstanding: 44.65m
  • Website: https://www.glaukos.com

Number of Employees


Location

  • Glaukos Corporation
  • 229 Avenida Fabricante
  • San Clemente
  • California
  • 92672
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GKOSNYSE (New York Stock Exchange)YesCommon StockUSUSDJun 2015
6GJDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2015

Biography

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to tre ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/29 00:35
End of Day Share Price2020/10/28 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.